dulaglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
glucagon-like peptide (GLP) analogues and agonists 4885 923950-08-7

Description:

MoleculeDescription

Synonyms:

  • dulaglutide
  • trulicity
  • LY2189265
a glucagon-like peptide-1 receptor agonist; GLP-1 immunoglobulin G (IgG4) Fc fusion protein with extended activity
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.16 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Nov. 22, 2014 EMA
Sept. 18, 2014 FDA ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 645.51 16.13 335 17893 94911 90515308
Nausea 504.13 16.13 838 17390 1109478 89500741
Injection site pain 494.23 16.13 350 17878 173349 90436870
Glycosylated haemoglobin increased 481.17 16.13 162 18066 15400 90594819
Accidental underdose 439.91 16.13 88 18140 1003 90609216
Extra dose administered 278.13 16.13 94 18134 9024 90601195
Incorrect dose administered 261.58 16.13 175 18053 78755 90531464
Diabetic ketoacidosis 249.78 16.13 114 18114 24293 90585926
Vomiting 181.41 16.13 451 17777 787842 89822377
Inappropriate schedule of product administration 165.22 16.13 176 18052 149757 90460462
Product dose omission issue 161.95 16.13 243 17985 291444 90318775
Injection site pruritus 156.12 16.13 110 18118 53724 90556495
Injection site haemorrhage 156.06 16.13 87 18141 28231 90581988
Pancreatitis 153.94 16.13 121 18107 69705 90540514
Injection site erythema 148.11 16.13 137 18091 98365 90511854
Accidental overdose 145.35 16.13 83 18145 28190 90582029
Euglycaemic diabetic ketoacidosis 139.57 16.13 51 18177 6150 90604069
Lactic acidosis 139.15 16.13 100 18128 50363 90559856
Product administered at inappropriate site 131.33 16.13 44 18184 4107 90606112
Injury associated with device 124.31 16.13 43 18185 4421 90605798
Acute kidney injury 118.98 16.13 223 18005 320164 90290055
Diabetic metabolic decompensation 113.58 16.13 33 18195 1924 90608295
Hypoglycaemia 112.49 16.13 101 18127 69747 90540472
Blood glucose abnormal 92.88 16.13 43 18185 9449 90600770
Injection site mass 90.42 16.13 56 18172 22034 90588185
Injection site bruising 84.92 16.13 76 18152 52231 90557988
Blood glucose decreased 82.48 16.13 54 18174 23375 90586844
Diarrhoea 77.66 16.13 383 17845 938807 89671412
Injection site rash 71.45 16.13 50 18178 24123 90586096
Abdominal pain upper 68.40 16.13 183 18045 332491 90277728
Injection site urticaria 62.14 16.13 41 18187 17970 90592249
Pancreatic carcinoma 60.99 16.13 31 18197 8346 90601873
Pancreatitis acute 60.90 16.13 51 18177 32064 90578155
Eructation 58.75 16.13 33 18195 10849 90599370
Diabetes mellitus inadequate control 58.40 16.13 40 18188 18644 90591575
Systemic lupus erythematosus 57.31 16.13 4 18224 361892 90248327
Ketoacidosis 56.78 16.13 26 18202 5569 90604650
Infusion related reaction 54.90 16.13 9 18219 416771 90193448
Arthropathy 48.02 16.13 8 18220 366234 90243985
Transcription medication error 47.60 16.13 11 18217 256 90609963
Wrong technique in product usage process 47.45 16.13 65 18163 71506 90538713
Contraindicated product administered 46.71 16.13 5 18223 320134 90290085
Impaired gastric emptying 46.24 16.13 30 18198 12779 90597440
Dehydration 46.16 16.13 113 18115 194334 90415885
Wound 46.13 16.13 4 18224 302976 90307243
Stomatitis 43.59 16.13 3 18225 274695 90335524
Injection site swelling 42.19 16.13 56 18172 59783 90550436
Treatment failure 41.29 16.13 6 18222 303922 90306297
Blood glucose fluctuation 40.51 16.13 20 18208 5063 90605156
Accidental exposure to product 40.12 16.13 46 18182 42320 90567899
COVID-19 39.93 16.13 98 18130 168745 90441474
Underdose 38.77 16.13 51 18177 53966 90556253
Systemic infection 38.68 16.13 19 18209 4756 90605463
Hyperglycaemia 37.95 16.13 49 18179 50921 90559298
Joint swelling 37.39 16.13 28 18200 503272 90106947
Injection site injury 37.28 16.13 12 18216 987 90609232
Weight decreased 36.35 16.13 162 18066 379748 90230471
Impaired healing 35.90 16.13 3 18225 234196 90376023
Lichen planus 34.85 16.13 15 18213 2776 90607443
Therapeutic product effect decreased 32.35 16.13 8 18220 277563 90332656
Illness 31.49 16.13 58 18170 81911 90528308
Thirst decreased 29.96 16.13 8 18220 341 90609878
Hyperglycaemic hyperosmolar nonketotic syndrome 29.84 16.13 11 18217 1358 90608861
Fungal infection 28.66 16.13 39 18189 42622 90567597
Lipase increased 28.29 16.13 21 18207 11090 90599129
Blood calcitonin increased 27.05 16.13 5 18223 36 90610183
Coronavirus test positive 26.39 16.13 9 18219 886 90609333
Musculoskeletal stiffness 25.41 16.13 14 18214 296518 90313701
Blister 24.99 16.13 10 18218 254988 90355231
Glomerular filtration rate decreased 24.35 16.13 23 18205 16909 90593310
Maternal exposure during pregnancy 24.28 16.13 22 18206 360041 90250178
Ketosis 23.33 16.13 8 18220 801 90609418
Toxicity to various agents 22.69 16.13 15 18213 287831 90322388
Intercepted product selection error 22.57 16.13 4 18224 22 90610197
Injury 22.39 16.13 6 18222 197343 90412876
Exposure during pregnancy 22.32 16.13 10 18218 238400 90371819
Pneumonia 22.09 16.13 61 18167 637998 89972221
Hepatic enzyme increased 22.07 16.13 24 18204 360712 90249507
Fibromyalgia 22.06 16.13 7 18221 206262 90403957
C-reactive protein increased 21.57 16.13 5 18223 181384 90428835
Injection site irritation 21.50 16.13 14 18214 6001 90604218
Rheumatoid arthritis 21.23 16.13 25 18203 362589 90247630
Glycosylated haemoglobin decreased 21.01 16.13 7 18221 642 90609577
Vision blurred 20.94 16.13 59 18169 110234 90499985
Product storage error 20.91 16.13 23 18205 20218 90590001
Vomiting projectile 20.24 16.13 9 18219 1800 90608419
Feeding disorder 20.03 16.13 21 18207 17491 90592728
Blindness transient 19.82 16.13 12 18216 4531 90605688
Diabetic retinopathy 19.67 16.13 10 18218 2692 90607527
Product prescribing error 19.40 16.13 27 18201 30118 90580101
Completed suicide 19.37 16.13 3 18225 145055 90465164
Nasopharyngitis 18.96 16.13 33 18195 407071 90203148
Increased appetite 18.89 16.13 17 18211 11748 90598471
Drug effect less than expected 18.84 16.13 13 18215 6125 90604094
Neutropenia 18.71 16.13 11 18217 224893 90385326
Off label use 18.47 16.13 138 18090 1102114 89508105
Device difficult to use 18.25 16.13 20 18208 17505 90592714
Dermatitis atopic 18.15 16.13 23 18205 23449 90586770
Hypertriglyceridaemia 18.07 16.13 14 18214 7875 90602344
Diabetic ketosis 17.96 16.13 6 18222 555 90609664
Joint range of motion decreased 17.68 16.13 3 18225 135640 90474579
Decreased activity 17.61 16.13 14 18214 8178 90602041
Intentional product use issue 17.50 16.13 11 18217 216881 90393338
Irritable bowel syndrome 17.47 16.13 10 18218 207438 90402781
Injection site nodule 17.44 16.13 11 18217 4462 90605757
Arthralgia 17.43 16.13 89 18139 778433 89831786
Product use issue 17.00 16.13 25 18203 329894 90280325
Injection site coldness 17.00 16.13 4 18224 101 90610118
Injection site discomfort 16.88 16.13 12 18216 5928 90604291
Idiopathic CD4 lymphocytopenia 16.70 16.13 3 18225 18 90610201
Injection site induration 16.56 16.13 15 18213 10453 90599766
Cholelithiasis 16.33 16.13 34 18194 52472 90557747
Bacterial translocation 16.21 16.13 6 18222 750 90609469

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 474.26 16.47 296 13587 73403 42534049
Accidental underdose 351.62 16.47 73 13810 598 42606854
Glycosylated haemoglobin increased 337.99 16.47 135 13748 12789 42594663
Injection site pain 326.38 16.47 214 13669 57584 42549868
Extra dose administered 250.28 16.47 87 13796 5582 42601870
Pancreatitis 246.02 16.47 161 13722 43107 42564345
Diabetic ketoacidosis 212.77 16.47 116 13767 22251 42585201
Nausea 207.32 16.47 420 13463 396379 42211073
Diabetes mellitus inadequate control 169.41 16.47 88 13795 15302 42592150
Inappropriate schedule of product administration 167.28 16.47 180 13703 95722 42511730
Pancreatitis acute 152.94 16.47 109 13774 33455 42573997
Incorrect dose administered 140.20 16.47 125 13758 52849 42554603
Diarrhoea 123.10 16.47 378 13505 460471 42146981
Injection site mass 117.81 16.47 57 13826 8518 42598934
Vomiting 112.52 16.47 273 13610 289450 42318002
Euglycaemic diabetic ketoacidosis 110.38 16.47 48 13835 5612 42601840
Injection site haemorrhage 98.25 16.47 56 13827 11680 42595772
Injection site erythema 97.55 16.47 68 13815 20127 42587325
Accidental overdose 89.44 16.47 74 13809 28256 42579196
Lactic acidosis 87.76 16.47 90 13793 45171 42562281
Hyperglycaemia 81.42 16.47 87 13796 45772 42561680
Metabolic acidosis 81.03 16.47 92 13791 51766 42555686
Injection site pruritus 79.05 16.47 45 13838 9360 42598092
Ketoacidosis 77.83 16.47 37 13846 5315 42602137
Glycosylated haemoglobin abnormal 75.53 16.47 18 13865 290 42607162
Blood glucose abnormal 68.17 16.47 37 13846 7016 42600436
Product dose omission issue 66.81 16.47 152 13731 154213 42453239
Pancreatic carcinoma 60.42 16.47 38 13845 9468 42597984
Weight decreased 56.42 16.47 172 13711 207776 42399676
Toxicity to various agents 56.30 16.47 5 13878 229131 42378321
Underdose 55.66 16.47 45 13838 16621 42590831
Obstructive pancreatitis 55.27 16.47 17 13866 738 42606714
Hyperlipasaemia 54.77 16.47 16 13867 581 42606871
Hypoglycaemia 52.57 16.47 80 13803 59774 42547678
Eructation 50.86 16.47 28 13855 5458 42601994
Lipase increased 49.66 16.47 35 13848 10531 42596921
Injection site swelling 48.74 16.47 42 13841 16931 42590521
Gastrointestinal disorder 40.45 16.47 62 13821 46591 42560861
Injection site bruising 40.36 16.47 32 13851 11493 42595959
Blood glucose decreased 38.44 16.47 34 13849 14185 42593267
Injury associated with device 37.89 16.47 15 13868 1382 42606070
Product storage error 37.02 16.47 30 13853 11110 42596342
Injection site rash 36.71 16.47 23 13860 5689 42601763
Injection site discomfort 36.51 16.47 17 13866 2329 42605123
Acute kidney injury 34.63 16.47 221 13662 367116 42240336
Pancreatic carcinoma metastatic 34.51 16.47 18 13865 3148 42604304
Febrile neutropenia 32.58 16.47 10 13873 185693 42421759
Dyspepsia 31.77 16.47 52 13831 41300 42566152
Injection site urticaria 30.63 16.47 17 13866 3366 42604086
Decreased appetite 28.91 16.47 132 13751 193005 42414447
Hyperkinetic heart syndrome 28.91 16.47 7 13876 121 42607331
Pyrexia 28.68 16.47 53 13830 393989 42213463
Disease progression 28.53 16.47 6 13877 143650 42463802
Abdominal discomfort 28.04 16.47 70 13813 75185 42532267
Pneumonia 27.97 16.47 60 13823 422089 42185363
Impaired gastric emptying 26.61 16.47 17 13866 4349 42603103
Injection site reaction 26.43 16.47 29 13854 15692 42591760
Off label use 25.13 16.47 115 13768 638220 41969232
Ketonuria 24.78 16.47 9 13874 655 42606797
Abdominal pain 24.75 16.47 125 13758 190346 42417106
Product administered at inappropriate site 23.84 16.47 14 13869 3084 42604368
Gastric dilatation 23.00 16.47 9 13874 804 42606648
Wrong drug 22.24 16.47 6 13877 162 42607290
Product monitoring error 21.59 16.47 15 13868 4408 42603044
Drug abuse 21.59 16.47 4 13879 104767 42502685
Completed suicide 21.40 16.47 3 13880 96462 42510990
Respiratory failure 20.56 16.47 8 13875 128124 42479328
Injection site nodule 19.95 16.47 11 13872 2150 42605302
Gangrene 19.61 16.47 15 13868 5111 42602341
Abdominal pain upper 19.29 16.47 65 13818 82544 42524908
Anaemia 19.22 16.47 39 13844 280239 42327213
Echocardiogram abnormal 19.14 16.47 9 13874 1261 42606191
Flatulence 18.46 16.47 31 13852 25121 42582331
Hyperamylasaemia 18.01 16.47 7 13876 614 42606838
Polyuria 17.76 16.47 19 13864 9992 42597460
Adenocarcinoma pancreas 17.75 16.47 9 13874 1485 42605967
White blood cell count decreased 17.53 16.47 7 13876 110389 42497063
Diabetic metabolic decompensation 17.50 16.47 10 13873 2092 42605360
Injection site injury 17.44 16.47 6 13877 372 42607080
Orchitis 16.87 16.47 10 13873 2241 42605211
Toe amputation 16.85 16.47 11 13872 2918 42604534
Spermatic cord inflammation 16.69 16.47 3 13880 10 42607442

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 545.27 15.14 342 22936 132154 110433867
Glycosylated haemoglobin increased 544.71 15.14 200 23078 23419 110542602
Diabetic ketoacidosis 392.96 15.14 187 23091 41871 110524150
Injection site pain 263.03 15.14 250 23028 177672 110388349
Euglycaemic diabetic ketoacidosis 262.60 15.14 97 23181 11526 110554495
Lactic acidosis 260.09 15.14 189 23089 92622 110473399
Pancreatitis 251.99 15.14 186 23092 93347 110472674
Pancreatitis acute 228.66 15.14 148 23130 60126 110505895
Nausea 204.11 15.14 645 22633 1235045 109330976
Acute kidney injury 194.97 15.14 419 22859 635011 109931010
Diabetes mellitus inadequate control 186.22 15.14 101 23177 29674 110536347
Vomiting 182.95 15.14 510 22768 910165 109655856
Extra dose administered 181.00 15.14 75 23203 12084 110553937
Accidental underdose 179.67 15.14 44 23234 1261 110564760
Hyperglycaemia 130.22 15.14 122 23156 84968 110481053
Hypoglycaemia 127.35 15.14 139 23139 115965 110450056
Diarrhoea 126.31 15.14 523 22755 1138982 109427039
Metabolic acidosis 121.02 15.14 126 23152 99618 110466403
Incorrect dose administered 118.77 15.14 127 23151 103514 110462507
Ketoacidosis 116.49 15.14 52 23226 10035 110555986
Product dose omission issue 112.18 15.14 224 23054 321558 110244463
Pancreatic carcinoma 111.60 15.14 57 23221 14815 110551206
Diabetic metabolic decompensation 101.06 15.14 36 23242 3853 110562168
Inappropriate schedule of product administration 84.80 15.14 153 23125 203484 110362537
Injury associated with device 82.38 15.14 32 23246 4357 110561664
Accidental overdose 80.58 15.14 75 23203 51759 110514262
Injection site pruritus 71.76 15.14 70 23208 51188 110514833
Blood glucose abnormal 70.30 15.14 40 23238 12876 110553145
Injection site erythema 69.15 15.14 92 23186 94084 110471937
Lipase increased 66.25 15.14 44 23234 18628 110547393
Injection site haemorrhage 65.76 15.14 55 23223 32973 110533048
Blood glucose decreased 60.57 15.14 50 23228 29438 110536583
Eructation 54.45 15.14 35 23243 14022 110551999
Obstructive pancreatitis 54.25 15.14 17 23261 1224 110564797
Weight decreased 52.38 15.14 216 23062 467841 110098180
Product administered at inappropriate site 50.38 15.14 24 23254 5369 110560652
Infusion related reaction 49.51 15.14 10 23268 381152 110184869
Wrong technique in product usage process 48.90 15.14 75 23203 87273 110478748
Toxicity to various agents 48.88 15.14 20 23258 480535 110085486
Hyperlipasaemia 47.24 15.14 16 23262 1473 110564548
Dehydration 46.61 15.14 147 23131 279364 110286657
Pancreatic carcinoma metastatic 46.59 15.14 21 23257 4143 110561878
Injection site mass 44.93 15.14 39 23239 24574 110541447
Systemic lupus erythematosus 41.95 15.14 3 23275 254335 110311686
Impaired gastric emptying 39.34 15.14 28 23250 13247 110552774
COVID-19 38.23 15.14 126 23152 244934 110321087
Transcription medication error 37.28 15.14 11 23267 646 110565375
Ketosis 37.27 15.14 14 23264 1740 110564281
Lower respiratory tract infection 37.02 15.14 4 23274 243102 110322919
Blood glucose fluctuation 37.01 15.14 22 23256 7676 110558345
Injection site rash 36.61 15.14 34 23244 23385 110542636
Glycosylated haemoglobin abnormal 35.97 15.14 10 23268 474 110565547
Stomatitis 35.27 15.14 7 23271 270235 110295786
Arthropathy 32.57 15.14 10 23268 287512 110278509
Ketonuria 32.49 15.14 12 23266 1423 110564598
Completed suicide 32.22 15.14 6 23272 242375 110323646
Product prescribing error 31.47 15.14 46 23232 51285 110514736
Lichen planus 31.32 15.14 15 23263 3395 110562626
Hyperkinetic heart syndrome 30.94 15.14 7 23271 141 110565880
Accidental exposure to product 30.93 15.14 45 23233 49963 110516058
Impaired healing 30.56 15.14 3 23275 196714 110369307
Injection site bruising 30.08 15.14 45 23233 51218 110514803
Joint swelling 29.29 15.14 30 23248 442815 110123206
Increased appetite 27.88 15.14 24 23254 14953 110551068
Drug abuse 26.80 15.14 3 23275 177408 110388613
Pneumonia 26.63 15.14 95 23183 876619 109689402
Decreased appetite 25.81 15.14 180 23098 475666 110090355
Diabetic ketosis 25.59 15.14 9 23269 927 110565094
Blood calcitonin increased 25.26 15.14 5 23273 51 110565970
Systemic infection 25.22 15.14 19 23259 9800 110556221
Injection site urticaria 25.01 15.14 24 23254 17191 110548830
Product monitoring error 24.56 15.14 18 23260 8909 110557112
Thirst decreased 24.55 15.14 7 23271 364 110565657
Contraindicated product administered 24.15 15.14 11 23267 248256 110317765
Adenocarcinoma pancreas 24.01 15.14 11 23267 2252 110563769
Disease progression 23.45 15.14 11 23267 244023 110321998
Wound 23.42 15.14 10 23268 234427 110331594
Device difficult to use 23.22 15.14 24 23254 18781 110547240
Wrong drug 23.20 15.14 7 23271 444 110565577
Cholelithiasis 23.05 15.14 45 23233 63377 110502644
Treatment failure 23.02 15.14 15 23263 277219 110288802
Off label use 22.92 15.14 204 23074 1499981 109066040
Orchitis 22.79 15.14 10 23268 1852 110564169
Coronavirus test positive 22.67 15.14 9 23269 1298 110564723
Injection site swelling 22.65 15.14 44 23234 61746 110504275
Febrile neutropenia 22.64 15.14 20 23258 316747 110249274
Neck dissection 22.40 15.14 3 23275 0 110566021
Maternal exposure during pregnancy 22.26 15.14 13 23265 254870 110311151
Therapeutic product effect decreased 22.00 15.14 12 23266 244304 110321717
Gastric dilatation 21.72 15.14 10 23268 2071 110563950
Injection site nodule 21.62 15.14 13 23265 4633 110561388
Fibromyalgia 21.13 15.14 5 23273 170904 110395117
Product administration interrupted 20.83 15.14 18 23260 11274 110554747
Musculoskeletal stiffness 20.81 15.14 17 23261 279805 110286216
Abdominal pain 20.59 15.14 181 23097 512808 110053213
Injection site injury 20.54 15.14 8 23270 1096 110564925
Pyrexia 20.18 15.14 109 23169 898156 109667865
Irritable bowel syndrome 19.92 15.14 5 23273 164210 110401811
Toe amputation 19.83 15.14 12 23266 4326 110561695
Dysuria 19.82 15.14 41 23237 60190 110505831
Hepatic enzyme increased 19.81 15.14 23 23255 320869 110245152
Underdose 19.45 15.14 42 23236 63512 110502509
Illness 19.34 15.14 49 23229 82122 110483899
Blister 19.29 15.14 12 23266 227364 110338657
Drug level increased 18.75 15.14 35 23243 47684 110518337
Product storage error 18.73 15.14 23 23255 21705 110544316
Glycosylated haemoglobin decreased 18.67 15.14 7 23271 865 110565156
Ill-defined disorder 18.60 15.14 5 23273 156848 110409173
Blood ketone body increased 18.55 15.14 7 23271 881 110565140
Urine ketone body present 18.51 15.14 11 23267 3835 110562186
Intentional product use issue 18.51 15.14 15 23263 247891 110318130
Drug effect less than expected 18.44 15.14 14 23264 7306 110558715
Spermatic cord inflammation 18.24 15.14 3 23275 9 110566012
Hyperglycaemic hyperosmolar nonketotic syndrome 18.23 15.14 10 23268 2999 110563022
Hepatic steatosis 18.18 15.14 35 23243 48796 110517225
Glucose urine present 17.83 15.14 9 23269 2280 110563741
Bursitis 17.73 15.14 3 23275 129915 110436106
Amylase increased 17.33 15.14 17 23261 12502 110553519
Decreased activity 17.28 15.14 16 23262 10958 110555063
Pancreatitis necrotising 17.22 15.14 12 23266 5489 110560532
Hypoglycaemic coma 17.16 15.14 12 23266 5521 110560500
Insulin resistance 17.07 15.14 8 23270 1726 110564295
Nasopharyngitis 16.98 15.14 36 23242 394325 110171696
Blood triglycerides increased 16.98 15.14 23 23255 23903 110542118
Injection site discomfort 16.94 15.14 13 23265 6894 110559127
Miosis 16.93 15.14 22 23256 21961 110544060
Therapy non-responder 16.88 15.14 6 23272 157301 110408720
Diabetic neuropathy 16.78 15.14 13 23265 6986 110559035
Flatulence 16.57 15.14 35 23243 52114 110513907
Idiopathic CD4 lymphocytopenia 16.57 15.14 3 23275 18 110566003
Pancytopenia 16.52 15.14 12 23266 209601 110356420
Echocardiogram abnormal 16.51 15.14 9 23269 2665 110563356
Hyperamylasaemia 16.39 15.14 7 23271 1214 110564807
Blindness transient 16.36 15.14 12 23266 5944 110560077
Lumbosacral radiculoplexus neuropathy 16.19 15.14 4 23274 119 110565902
Wheezing 16.07 15.14 18 23260 255212 110310809
Injection site irritation 16.02 15.14 11 23267 4913 110561108
Dermatitis atopic 15.81 15.14 23 23255 25518 110540503
Constipation 15.26 15.14 128 23150 357658 110208363

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BJ05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D000097789 Glucagon-Like Peptide-1 Receptor Agonists
MeSH PA D007004 Hypoglycemic Agents
FDA EPC N0000178480 GLP-1 Receptor Agonist

Related Drugs by ATC class:

A10BJ Glucagon-like peptide-1 (GLP-1) analogues 5 drugs
albiglutideexenatideliraglutidelixisenatidesemaglutide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
WTT295HSY5 UNII
D09889 KEGG_DRUG
4033739 VUID
N0000191089 NUI
4033739 VANDF
C3179549 UMLSCUI
CHEMBL2108027 ChEMBL_ID
DB09045 DRUGBANK_ID
9164 INN_ID
C555680 MESH_SUPPLEMENTAL_RECORD_UI
7638 IUPHAR_LIGAND_ID
1551291 RXNORM
228834 MMSL
30573 MMSL
d08290 MMSL
015693 NDDF
714080005 SNOMEDCT_US
714081009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-1433 INJECTION, SOLUTION 0.75 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-1434 INJECTION, SOLUTION 1.50 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-2236 INJECTION, SOLUTION 3 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 0002-3182 INJECTION, SOLUTION 4.50 mg SUBCUTANEOUS BLA 36 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 50090-3483 INJECTION, SOLUTION 1.50 mg SUBCUTANEOUS BLA 34 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 50090-3484 INJECTION, SOLUTION 0.75 mg SUBCUTANEOUS BLA 34 sections
Trulicity HUMAN PRESCRIPTION DRUG LABEL 1 50090-5467 INJECTION, SOLUTION 3 mg SUBCUTANEOUS BLA 34 sections
TRULICITY HUMAN PRESCRIPTION DRUG LABEL 1 50090-6453 INJECTION, SOLUTION 0.75 mg SUBCUTANEOUS BLA 34 sections
TRULICITY HUMAN PRESCRIPTION DRUG LABEL 1 50090-6456 INJECTION, SOLUTION 1.50 mg SUBCUTANEOUS BLA 34 sections
TRULICITY HUMAN PRESCRIPTION DRUG LABEL 1 50090-6571 INJECTION, SOLUTION 3 mg SUBCUTANEOUS BLA 34 sections
TRULICITY HUMAN PRESCRIPTION DRUG LABEL 1 50090-7589 INJECTION, SOLUTION 4.50 mg SUBCUTANEOUS BLA 35 sections